If a bird calls, will we detect it? Factors that can influence the detectability of calls on automated recording units in field conditions by Abby Thomas (9288104)

Shape-Based Reprofiling of FDA-Approved Drugs for the H₁ Histamine Receptor by Sridhar R. Vasudevan (589877)

“…Reprofiling of existing drugs to treat conditions not originally targeted is an attractive means of addressing the problem of a decreasing stream of approved drugs. …”

Postnatal decrease in PV+ cortical interneurons in Fgfr1 mutant mice. by Karen Müller Smith (613941)

“…<p>PV and GFP immunostaining in 8 week old <i>Fgfr1^f/f;Gad67-GFP+</i> control (<b>A</b>, n = 5) and <i>Fgfr1^f/f;hGFAP-Cre;Gad67-GFP+</i> mutant mice (<b>B</b>, n = 9). Scale bar is 50 µm in <b>A</b>,<b>B</b>. Stereological analysis show significant decreases in in both GFP and PV immunopositive cells in Fgfr1 mutant mice as compared to littermate controls (<b>C</b>). …”

Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice-1 by Chad A Dickey (26939)

“…Scale bar = 50 μm.…”

Advancing the science of NOWS research. by Sarah E. Maylott (14560785)

“…Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. We propose noninvasive clinical indicators of NOWS, including newborn neurobehavior, autonomic biomarkers, prenatal substance exposures, and socioeconomic environments. …”

Protocol measures. by Sarah E. Maylott (14560785)

“…Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. We propose noninvasive clinical indicators of NOWS, including newborn neurobehavior, autonomic biomarkers, prenatal substance exposures, and socioeconomic environments. …”

Cry variables. by Sarah E. Maylott (14560785)

“…Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. We propose noninvasive clinical indicators of NOWS, including newborn neurobehavior, autonomic biomarkers, prenatal substance exposures, and socioeconomic environments. …”

ACT and ISO decrease pathological changes in LPS-induced AKI mice. by Jing Lian (1671991)

Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides by Zufang Ba (11036420)

“…Phosphorylation can reduce toxicity and improve the stability of AMPs. Based on these, we designed a series of peptides and their corresponding phosphorylated forms. …”

Increased claudin-2 expression is not paralled by decreased transepithelial electrical resistance. by Peggy Bodammer (584093)

“…<p>Apical stimulation of filter-grown differentiated 14 days postconfluent Caco-2 cells with IL-6 (50 ng/ml) decreased transepithelial electrical resistance (TER) after 24 h compared to unstimulated controls (complete media, CM). …”

SAA and saaHDL decrease adiponectin secretion by hMADS adipocytes. by Aurélie Faty (169741)

HRs, 95% CIs, and <i>p</i>-values for the association of duration of lithium exposure with the development of dementia (and its subtypes) by Cox proportional hazards models. by Shanquan Chen (3417512)

Subjects:

Mean sum of squares for morphological parameters of eight mung bean genotypes grown under Cd and pretreatments of GA₃, SA and proline prior to Cd. by Meher Hassan (11502144)

Induced abortion rates per 1000 women ≤ 19 years by Nordic country, 1974–2022. by Finn Egil Skjeldestad (7821716)

Subjects:

Induced abortions per 1000 women 15–49 years, Nordic countries, 1970–2022. by Finn Egil Skjeldestad (7821716)

Subjects:

Fig 7 - by Finn Egil Skjeldestad (7821716)

Subjects:

Proportion of 2^nd trimester induced abortions on fetal indications by gestational ages 13–15 weeks/16-22 weeks, Finland, and Norway. by Finn Egil Skjeldestad (7821716)

Subjects:

Selected age-specific induced abortion rates per 1000 women/year, Sweden (bold lines) and Finland (dotted lines), 1970–2022. by Finn Egil Skjeldestad (7821716)

Subjects:

Gestational age ≥ 12 and ≥ 13 weeks at the time for termination, Sweden, Norway, Finland, and Denmark, 1974–2022. by Finn Egil Skjeldestad (7821716)

Subjects:

Gestational age ≤ 8 weeks (upper panel) and ≥ 13 weeks (lower panel) at the time of termination, Nordic countries, 1974–2022. by Finn Egil Skjeldestad (7821716)

Subjects: